Takeda logo

EGFR EXON20 Insertion+ Non-Small Cell Lung Cancer (NSCLC)

EGFR EXON20 Insertion+ Non-Small Cell Lung Cancer (NSCLC)

Overview

Similar to anaplastic lymphoma kinase-positive (ALK+) NSCLC, EGFR-positive NSCLC is driven by a mutation in the EGFR (epidermal growth factor receptor) gene. EGFR mutations occur predominantly in exons 18, 19, 20, or 21.

Although rare, insertions and/or duplications in exon 20 account for ~1-2% of all NSCLC, equating to over 35,000 new cases each year globally. 1-3

Historically, patients with EGFR exon 20 insertions have been treated with chemotherapy, although EGFR tyrosine kinase inhibitors (TKIs) or immunotherapies are also used; however, all of these options are associated with limited efficacy. To identify patients with EGFR exon20 insertion mutations, comprehensive genomic testing is crucial.

Expanded genomic testing and the continued investigation of novel therapies are needed to help identify and ultimately improve outcomes for people living with EGFR exon20 insertion+ mNSCLC.

Resources

1 Riess JW, Gandara DR, Frampton GM, et al. J Thorac Oncol. 2018;13(10):1560-1568. 2 Fang W, Huang Y, Hong S, et al. BMC cancer 2019;19,1-9. 3 Oxnard GR, Lo PC, Nishino M, et al. J Thorac Oncol. 2013;8(2):179-184.

Explore More

Card image
Discovering and developing innovative therapies to deliver potentially transformative treatments.
Card image
Decades of leadership in Oncology with a diverse and robust pipeline.
Card image
We are committed to helping people with cancer navigate every part of their journey.

All trademarks are the property of their respective owners.

©2023 Takeda Pharmaceuticals U.S.A., Inc.

All rights reserved.   01/23